Author

D. Y. Moore

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

A. L. Smith· 2 shared D. El-Gamal· 2 shared A. Kallam· 1 shared A. Muralidharan· 1 shared A. P. Eiken· 1 shared C. R. D'Angelo· 1 shared D. Gilham· 1 shared E. Kulikowski· 1 shared

Activity by Year

2021-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 30 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. L. Smith

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

A novel triple-action inhibitor targeting B-cell receptor signaling and BRD4 demonstrates preclinical activity in chronic lymphocytic leukemia

A. L. Smith, A. P. Eiken, D. Y. Moore, L. T. Umeta, L. M. Smith, E. R. Lyden, C. R. D'Angelo, A. Kallam, J. M. Vose, T. G. Kutateladze, D. El-Gamal

This study shows that SRX3305, a triple-action inhibitor targeting BTK, PI3K, and BRD4, reduces CLL cell proliferation, promotes apoptosis, and blocks migration in preclinical models.

bioRxiv · May 11, 2022Cancer Biology

Bromodomain and Extraterminal Protein Inhibitor, Apabetalone (RVX-208), Reduces ACE2 Expression and Attenuates SARS-CoV-2 Infection in vitro

D. Gilham, A. L. Smith, L. Fu, D. Y. Moore, A. Muralidharan, S. P. M. Reid, S. C. Stotz, J. O. Johansson, M. Sweeney, N. C. Wong, E. Kulikowski, D. El-Gamal

This study shows apabetalone reduces ACE2 and DPP4 expression and inhibits SARS-CoV-2 infection in vitro, suggesting it could be a potential therapeutic for COVID-19.

bioRxiv · Mar 10, 2021Pharmacology & Toxicology